Targeting Oncogenic Activity and Signalling of Mutant Receptor Tyrosine Kinase FLT3

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Fms-like tyrosine kinase 3 (FLT3) is crucial for hematopoietic progenitor development.
• Oncogenic FLT3 mutations, especially internal tandem duplications (ITDs), are common in acute myeloid leukaemia (AML) and linked to poor prognosis.
• Targeting FLT3-mutated leukaemic stem cells is vital for treating relapsed/refractory AML.

Purpose of the Study:

• To review the current understanding of oncogenic FLT3 regulation in AML.
• To explore novel therapeutic strategies beyond approved tyrosine kinase inhibitors.
• To discuss alternative treatment options targeting FLT3 aberrant signaling.

Main Methods:

• Literature review of current knowledge on FLT3 mutations in AML.
• Analysis of molecular mechanisms driving FLT3-dependent cell transformation.
• Exploration of emerging therapeutic targets and pathways.

Main Results:

• Mutant FLT3, particularly FLT3-ITD, confers constitutive activity, promoting leukaemic cell survival and proliferation.
• Resistance to existing FLT3 inhibitors often arises from secondary mutations or bypass pathways.
• Understanding PTP regulation and FLT3 biogenesis offers new therapeutic avenues.

Conclusions:

• Novel treatments targeting FLT3 aberrations are needed to overcome resistance in AML.
• Investigating protein tyrosine phosphatases and FLT3 activation mechanisms may yield effective therapies.
• Alternative strategies hold promise for improving outcomes in relapsed/refractory AML patients.